Awaiting development: Guidance and quality standards

Showing 231 to 240 of 304

Guidance and quality standards awaiting development
Title	Type
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]	Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814	Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433	Technology appraisal guidance
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237	Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]	Technology appraisal guidance
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042	Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [TS ID 12095]	Technology appraisal guidance
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]	Technology appraisal guidance
Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458	Technology appraisal guidance
Semaglutide for treating type 2 diabetes (ID1450)	Technology appraisal guidance